TGFB1 and sarcoidosis: Only one trial has been conducted, where the CysLTR1 receptor antagonist Montelukast was tested in a small seven sarcoidosis patient cohort, and was found to inhibit TGFβ mRNA expression and fibrosis-favoring effects on myofibroblasts in vitro29.